The Biosensor is a Platform for Multiple Diagnostic Tests
World-first Organic Thin Film Transistor (OTFT) technology
The Biosensor Platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.
By altering the detection element (region A) depending on the specific analyte of interest, we have the ability to produce a whole portfolio of non-invasive, real-time, saliva-based diagnostic tests.
Because both the core OTFT sensing element and the mechanism of action remains the same, tests developed from the Biosensor Platform have the potential to be printed at scale, at a low cost.
The story of the Biosensor
Professor Paul Dastoor and University of Newcastle team began research into conducting polymers.
IP for Organic Thin-Film Transistor (OTFT) technology filed.
“Detection of saliva-range glucose concentrations using organic thin-film transistors”, Applied Physics Letters, 105, 043303 (2014).
The iQ Group Global acquires OTFT technology for diabetes management and accelerates development into medical device.
Patent: US 9,766,199B2
Original IP protected to 2033, with more patents to be filed. Ongoing development by original scientific team.
Leadership team established for GBS Inc.
BIOSENSOR PLATFORM PIPELINE EXTENDED
The iQ Group Global announces extension of research and development of biosensor for additional indications including cancer, allergen and hormone biomarkers.
CHINA PATENT GRANTED
GenomeWeb acknowledges the Saliva Glucose Biosensor as leading the race to the “holy grail” of life sciences.
commences for De Novo classification of the Saliva Glucose Biosensor.
COVID-19 ANTIBODY PROGRAM
Collaboration with Wyss Institute for Biologically Inspired Engineering at Harvard University commences for COVID-19 antibody program.